Hansa Biopharma AB (GB:0RC7)
LSE:0RC7
0RC7 Stock Chart & Stats
kr29.04
-kr19.80(-18.94%)
At close: 4:00 PM EDT
kr29.04
-kr19.80(-18.94%)
Day’s Range― - ―
52-Week Rangekr23.34 - kr42.96
Previous CloseN/A
Volume2.39K
Average Volume (3M)28.96K
Market Cap
kr3.51B
Enterprise Valuekr3.20B
Total Cash (Recent Filing)kr676.46M
Total Debt (Recent Filing)kr1.14B
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Jul 22, 2026EPS Estimate
0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.83
Shares Outstanding101,763,220
10 Day Avg. Volume43,390
30 Day Avg. Volume28,964
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)-31.35
Price to Sales (P/S)12.55
P/FCF Ratio-5.08
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr103.00Price Target Upside254.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.51
Revenue Forecast (FY)kr251.52M
Bulls Say, Bears Say
Bulls Say
Proprietary IgG‑cleaving PlatformHansa’s IgG‑cleaving enzyme platform is a durable competitive asset addressing antibody‑mediated barriers in transplantation. A differentiated mechanism creates high entry barriers for competitors, supports niche pricing and specialist adoption, and underpins further indication expansion and partnerships.
Advancing U.S./EU Regulatory PathProgressing BLA review and planned EMA filing/PDUFA create structural upside: U.S. approval and full EU approval would expand reimbursed addressable markets, enable a sustained commercial rollout, and materially increase predictable revenue potential beyond current regional sales volatility.
Promising Next‑generation Program (5487)HNSA‑5487’s strong first‑in‑human pharmacodynamics and lower anti‑drug antibody signal suggest longer duration and improved tolerability versus the current product. This pipeline asset can broaden indications (GBS briefing submitted) and reduce single‑product reliance if later‑stage results hold.
Bears Say
High Leverage And Negative EquityElevated debt and negative shareholders’ equity materially weaken financial flexibility. This structural leverage raises refinancing and dilution risk, constrains investment capacity for a U.S. launch and commercial scale‑up, and reduces the balance sheet’s ability to absorb shocks over the coming months.
Sustained Cash Burn And Negative FCFMeaningful negative operating and free cash flow means the business remains dependent on external financing to fund operations and planned commercial expansion. Persistent cash burn can force financing that dilutes shareholders or slows product rollout and pipeline investment if capital markets tighten.
Revenue Decline And Allocation VolatilitySteep recent revenue declines and structural organ‑allocation variability create durable unpredictability in sales and cash timing. Transplant timing links sales/receivables to organ offers, limiting revenue visibility and complicating forecasting and working‑capital management during commercialization scaling.
0RC7 FAQ
What was Hansa Biopharma AB’s price range in the past 12 months?
Hansa Biopharma AB lowest share price was kr23.34 and its highest was kr42.96 in the past 12 months.
What is Hansa Biopharma AB’s market cap?
Hansa Biopharma AB’s market cap is kr3.51B.
When is Hansa Biopharma AB’s upcoming earnings report date?
Hansa Biopharma AB’s upcoming earnings report date is Jul 22, 2026 which is in 37 days.
How were Hansa Biopharma AB’s earnings last quarter?
Hansa Biopharma AB released its earnings results on Apr 23, 2026. The company reported -kr1.93 earnings per share for the quarter, missing the consensus estimate of -kr1.45 by -kr0.48.
Is Hansa Biopharma AB overvalued?
According to Wall Street analysts Hansa Biopharma AB’s price is currently Undervalued.
Does Hansa Biopharma AB pay dividends?
Hansa Biopharma AB does not currently pay dividends.
What is Hansa Biopharma AB’s EPS estimate?
Hansa Biopharma AB’s EPS estimate is 0.17.
How many shares outstanding does Hansa Biopharma AB have?
Hansa Biopharma AB has 101,763,220 shares outstanding.
What happened to Hansa Biopharma AB’s price movement after its last earnings report?
Hansa Biopharma AB reported an EPS of -kr1.93 in its last earnings report, missing expectations of -kr1.45. Following the earnings report the stock price went down -9.098%.
Which hedge fund is a major shareholder of Hansa Biopharma AB?
Currently, no hedge funds are holding shares in GB:0RC7
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hansa Biopharma AB
Hansa Biopharma AB (publ) is a biopharmaceutical firm dedicated to developing immunomodulatory therapies. Leveraging its unique enzyme technology platform, the company targets treatments that facilitate organ transplants and address rare autoimmune conditions driven by immunoglobulin G (IgG), alongside applications in gene therapy and cancer. Its primary drug candidate, Imlifidase, an enzyme therapy designed to cleave antibodies, is currently undergoing Phase 3 clinical trials for use in patients awaiting sensitized kidney transplants and those with anti-GBM antibody disease. Imlifidase is also in Phase 2 trials for treating antibody-mediated kidney transplant rejection and Guillain Barré syndrome. Further pipeline developments include NiceR (Novel immunoglobulin cleaving enzymes for Repeat dosing) for autoimmune diseases, transplantation, and oncology, as well as EnzE (Enzyme based antibody Enhancement) for cancer immunotherapy. Hansa Biopharma also has a preclinical research partnership with argenx BV, exploring the synergistic potential of their respective IgG-modulating technologies. Established in 2007, the company's headquarters are located in Lund, Sweden.
0RC7 Stock 12 Month Forecast
Average Price Target
kr103.00
▲(254.68% Upside)
Technical Analysis
BioInvent International AB
―
Saniona AB
―
Vicore Pharma Holding AB
―
Xspray Pharma AB
―
Cantargia AB
―
Options Prices
Currently, No data available
---